Hilleman, a joint-venture between Merck Sharp & Dohme Ltd. and the Wellcome Trust, recently received regulatory clearance for Phase I/II clinical studies for its cholera vaccine in Bangladesh.
Hilleman CEO On Cost Gains From A Simpler Cholera Vaccine
Hilleman Laboratories is confident that its oral cholera vaccine, with "multi-fold differentiation" can be manufactured at much lower costs than existing products such as Sanofi-owned Shantha Biotechnics Ltd.'s Shanchol and Valneva SE's Dukoral.